Andreas Martinsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andreas Martinsson has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Anders Jeppsson
Sahlgrenska University Hospital
12 shared publications - Amar Taha
University of Gothenburg
8 shared publications - Susanne J. Nielsen
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University , Gothenburg
7 shared publications Anders Jeppsson
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg, Sweden
6 shared publicationsEmma C Hansson
Department of Cardiothoracic Surgery, Sahlgrenska University Hospital , Gothenburg 413 45
6 shared publicationsSusanne J Nielsen
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg, Sweden
6 shared publications
Latest Publications
- Open Access
Permanent pacemaker implantation after cardiac surgery and long-term outcome
Background: Patients undergoing cardiac surgery are at risk of perioperative conduction system damage leading to permanent placement of a cardiac electronic implantable device (CIED) which is a common complication following cardiac surgery. Studies evaluating the long-term outcomes following permanent pacemaker implantation in cardiac surgery patients are contradictory and inconsistent. The current study aimed to evaluate the long-term outcome across the spectrum of cardiac surgery in a nationwide contemporary setting. Methods: All adult patients in Sweden, without previous CIED who had cardiac surgery between 2006 and 2020 were included. Data was obtained from nationwide registries. Cox proportional hazards models were used to account for comorbid conditions and perioperative characteristics and to evaluate the association between permanent pacemaker or implantable cardioverter defibrillator (ICD) implantation and the risk of all-cause mortality, cardiovascular mortality and heart failure hospitalisation. Results: Among 76 223 patients (mean age 67.8 years, 25% female), 2150 (2.8%) received a permanent pacemaker and 348 (0.5%) received an ICD within 30 days after surgery. During a mean follow-up of 6.8 years (SD 10.7), pacemaker implantation was associated with a higher risk of all-cause mortality (adjusted HR (aHR) 1.09, 95% CI 1.01 to 1.19) and heart failure hospitalisation (aHR 1.36, 95% CI 1.22 to 1.52). Cardiovascular mortality showed a similar but statistically non-significant trend. ICD implantation was not associated with all-cause mortality but was associated with increased risks of heart failure hospitalisation and cardiovascular mortality. Subgroup analyses did not show any significant interactions between comorbid conditions and outcomes. Conclusion: Permanent pacemaker implantation after cardiac surgery was associated with a higher risk of all-cause mortality and heart failure hospitalisation. These findings were consistent across cardiac surgical subtypes and underscore the need for careful long-term surveillance for these patients.
Open AccessPermanent pacemaker implantation after cardiac surgery and long-term outcome
Background: Patients undergoing cardiac surgery are at risk of perioperative conduction system damage leading to permanent placement of a cardiac electronic implantable device (CIED) which is a common complication following cardiac surgery. Studies evaluating the long-term outcomes following permanent pacemaker implantation in cardiac surgery patients are contradictory and inconsistent. The current study aimed to evaluate the long-term outcome across the spectrum of cardiac surgery in a nationwide contemporary setting. Methods: All adult patients in Sweden, without previous CIED who had cardiac surgery between 2006 and 2020 were included. Data was obtained from nationwide registries. Cox proportional hazards models were used to account for comorbid conditions and perioperative characteristics and to evaluate the association between permanent pacemaker or implantable cardioverter defibrillator (ICD) implantation and the risk of all-cause mortality, cardiovascular mortality and heart failure hospitalisation. Results: Among 76 223 patients (mean age 67.8 years, 25% female), 2150 (2.8%) received a permanent pacemaker and 348 (0.5%) received an ICD within 30 days after surgery. During a mean follow-up of 6.8 years (SD 10.7), pacemaker implantation was associated with a higher risk of all-cause mortality (adjusted HR (aHR) 1.09, 95% CI 1.01 to 1.19) and heart failure hospitalisation (aHR 1.36, 95% CI 1.22 to 1.52). Cardiovascular mortality showed a similar but statistically non-significant trend. ICD implantation was not associated with all-cause mortality but was associated with increased risks of heart failure hospitalisation and cardiovascular mortality. Subgroup analyses did not show any significant interactions between comorbid conditions and outcomes. Conclusion: Permanent pacemaker implantation after cardiac surgery was associated with a higher risk of all-cause mortality and heart failure hospitalisation. These findings were consistent across cardiac surgical subtypes and underscore the need for careful long-term surveillance for these patients.
- Open Access
- 16 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (5) , 356-364
Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study
Aims: Current guidelines recommend considering long-term oral anticoagulation in patients with new-onset post-operative atrial fibrillation (POAF) after cardiac surgery, balancing stroke and bleeding risk. However, no specific approach to bleeding risk assessment is provided. We explored in a proof-of-concept study whether a bleeding risk score can identify patients with POAF after coronary artery bypass grafting (CABG) with increased risk of post-discharge major bleeding. Methods and results: This observational cohort study included 4436 patients with POAF after CABG in 2009–2020 without oral anticoagulation. The four-item PRECISE-DAPT score (based on age, creatinine clearance, preoperative haemoglobin concentration, and previous bleeding) was calculated for all patients. Bleeding risk was defined as high (≥25 points), medium (16–24 points), or low (≤15 points). Associations between bleeding risk and major bleeding events during the first post-operative year were assessed by Cox regression. Discrimination was evaluated with C-statistics, and calibration was assessed by comparing expected and observed bleeding rates. Major bleeding occurred in 2.1% of patients during the first year. The score classified 36.0% of patients as high bleeding risk. The hazard ratio for high vs. low bleeding risk was 4.81 (95% CI 2.59–8.96). The area under the receiver operating characteristic curve was 0.68 (95% CI 0.63–0.73). Calibration showed good agreement between expected and observed bleeding events in patients with an annual bleeding risk up to 7%. Conclusion: A bleeding risk score can be used to stratify patients with POAF after CABG into groups with different post-discharge bleeding risk. Further studies are necessary to identify the optimal risk score and its role in oral anticoagulation decision pathway to improve clinical outcomes.
- 16 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (5) , 356-364
Open AccessBleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study
Aims: Current guidelines recommend considering long-term oral anticoagulation in patients with new-onset post-operative atrial fibrillation (POAF) after cardiac surgery, balancing stroke and bleeding risk. However, no specific approach to bleeding risk assessment is provided. We explored in a proof-of-concept study whether a bleeding risk score can identify patients with POAF after coronary artery bypass grafting (CABG) with increased risk of post-discharge major bleeding. Methods and results: This observational cohort study included 4436 patients with POAF after CABG in 2009–2020 without oral anticoagulation. The four-item PRECISE-DAPT score (based on age, creatinine clearance, preoperative haemoglobin concentration, and previous bleeding) was calculated for all patients. Bleeding risk was defined as high (≥25 points), medium (16–24 points), or low (≤15 points). Associations between bleeding risk and major bleeding events during the first post-operative year were assessed by Cox regression. Discrimination was evaluated with C-statistics, and calibration was assessed by comparing expected and observed bleeding rates. Major bleeding occurred in 2.1% of patients during the first year. The score classified 36.0% of patients as high bleeding risk. The hazard ratio for high vs. low bleeding risk was 4.81 (95% CI 2.59–8.96). The area under the receiver operating characteristic curve was 0.68 (95% CI 0.63–0.73). Calibration showed good agreement between expected and observed bleeding events in patients with an annual bleeding risk up to 7%. Conclusion: A bleeding risk score can be used to stratify patients with POAF after CABG into groups with different post-discharge bleeding risk. Further studies are necessary to identify the optimal risk score and its role in oral anticoagulation decision pathway to improve clinical outcomes.
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e048153
Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients
Background: Patients undergoing cardiac surgery face an increased risk of infective endocarditis (IE), a risk that may be further exacerbated by implantation of cardiac implantable electronic devices (CIED). This study aimed to assess the risk of IE after CIED implantation within 30 days of cardiac surgery and identify associated risk factors. Methods: All patients in Sweden, with no previous CIED, who underwent first‐time cardiac surgery between 2006 and 2020 were included in this nationwide registry‐based study. Cox proportional hazards models adjusted for demographic and clinical covariates were used to estimate the association between CIED implantation and the risk of IE. Results: Out of 73 367 patients, 2302 (3.1%) received a CIED within 30 days. Over a median follow‐up of 6.5 years (interquartile range, 3.2–10.1 years), 1556 patients (2.1%) developed IE. CIED implantation was associated with an increased IE risk (adjusted hazard ratio [aHR], 1.46 [95% CI, 1.20–1.77]). Patients with IE had a significantly higher risk of mortality compared with those without IE (aHR, 1.80 [95% CI, 1.67–1.94]; P <0.001). The type of cardiac surgery influenced IE risk, with valvular surgeries showing a higher incidence than coronary artery bypass grafting. Risk factors independently associated with IE included male sex, age at surgery, diabetes, and peripheral vascular disease. Conclusions: CIED implantation within 30 days after cardiac surgery is associated with an increased long‐term risk of IE and subsequent mortality. The type of surgery and patient comorbidities influence the risk.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e048153
Open AccessInfective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients
Background: Patients undergoing cardiac surgery face an increased risk of infective endocarditis (IE), a risk that may be further exacerbated by implantation of cardiac implantable electronic devices (CIED). This study aimed to assess the risk of IE after CIED implantation within 30 days of cardiac surgery and identify associated risk factors. Methods: All patients in Sweden, with no previous CIED, who underwent first‐time cardiac surgery between 2006 and 2020 were included in this nationwide registry‐based study. Cox proportional hazards models adjusted for demographic and clinical covariates were used to estimate the association between CIED implantation and the risk of IE. Results: Out of 73 367 patients, 2302 (3.1%) received a CIED within 30 days. Over a median follow‐up of 6.5 years (interquartile range, 3.2–10.1 years), 1556 patients (2.1%) developed IE. CIED implantation was associated with an increased IE risk (adjusted hazard ratio [aHR], 1.46 [95% CI, 1.20–1.77]). Patients with IE had a significantly higher risk of mortality compared with those without IE (aHR, 1.80 [95% CI, 1.67–1.94]; P <0.001). The type of cardiac surgery influenced IE risk, with valvular surgeries showing a higher incidence than coronary artery bypass grafting. Risk factors independently associated with IE included male sex, age at surgery, diabetes, and peripheral vascular disease. Conclusions: CIED implantation within 30 days after cardiac surgery is associated with an increased long‐term risk of IE and subsequent mortality. The type of surgery and patient comorbidities influence the risk.
- Open Access
INFECTIVE ENDOCARDITIS AFTER ARRHYTHMIA DEVICE IMPLANTATION IN CARDIAC SURGERY PATIENTS
Background: Patients undergoing cardiac surgery face an increased risk of infective endocarditis (IE), a risk that may be further exacerbated by implantation of cardiac implantable electronic devices (CIED). This study aimed to assess the risk of IE after CIED implantation within 30 days of cardiac surgery and identify associated risk factors. Methods: All patients in Sweden, with no previous CIED, who underwent first-time cardiac surgery between 2006 and 2020 were included in this nationwide registry-based study. Cox proportional hazards models adjusted for demographic and clinical covariates were used to estimate the association between CIED implantation and the risk of IE. Results: Out of 73,367 patients, 2,302 (3.1%) received a CIED within 30 days. Over a median follow-up of 6.5 years (interquartile range, 3.2–10.1 years), 1,556 patients (2.1%) developed IE. CIED implantation was associated with an increased IE risk (adjusted Hazard ratio (aHR) 1.46; 95% confidence interval (CI) 1.20-1.77). Patients with IE had a significantly higher risk of mortality compared to those without IE (aHR 1.80; 95% CI 1.67-1.94; p<0.001). The type of cardiac surgery influenced IE risk, with valvular surgeries showing a higher incidence than coronary artery bypass grafting. Risk factors independently associated with IE included male sex, age at surgery, diabetes mellitus, and peripheral vascular disease. Conclusions: CIED implantation within 30 days after cardiac surgery is associated with an increased long-term risk of IE and subsequent mortality. The type of surgery and patient comorbidities influence the risk. CLINICAL PERSPECTIVE: What is new?: In this large nationwide registry study, cardiac implantable electronic devices (CIEDs) placed within 30 days after cardiac surgery were associated with a substantial and persistent risk of infective endocarditis. The risk of infective endocarditis was influenced by the type of cardiac surgery and patient-specific factors, rather than the timing of device implantation. What are the clinical implications?: Among post–cardiac surgery patients at elevated risk for infective endocarditis (e.g., those undergoing valvular procedures) who require a CIED, selecting devices associated with lower infection risk—such as leadless pacemakers or non-transvenous ICDs—may be a preferable strategy when appropriate. The optimal timing of CIED implantation after cardiac surgery remains uncertain. When delaying implantation, the rationale should center on allowing for potential recovery of conduction abnormalities, rather than attempting to mitigate the risk of device-related infection.
Open AccessINFECTIVE ENDOCARDITIS AFTER ARRHYTHMIA DEVICE IMPLANTATION IN CARDIAC SURGERY PATIENTS
Background: Patients undergoing cardiac surgery face an increased risk of infective endocarditis (IE), a risk that may be further exacerbated by implantation of cardiac implantable electronic devices (CIED). This study aimed to assess the risk of IE after CIED implantation within 30 days of cardiac surgery and identify associated risk factors. Methods: All patients in Sweden, with no previous CIED, who underwent first-time cardiac surgery between 2006 and 2020 were included in this nationwide registry-based study. Cox proportional hazards models adjusted for demographic and clinical covariates were used to estimate the association between CIED implantation and the risk of IE. Results: Out of 73,367 patients, 2,302 (3.1%) received a CIED within 30 days. Over a median follow-up of 6.5 years (interquartile range, 3.2–10.1 years), 1,556 patients (2.1%) developed IE. CIED implantation was associated with an increased IE risk (adjusted Hazard ratio (aHR) 1.46; 95% confidence interval (CI) 1.20-1.77). Patients with IE had a significantly higher risk of mortality compared to those without IE (aHR 1.80; 95% CI 1.67-1.94; p<0.001). The type of cardiac surgery influenced IE risk, with valvular surgeries showing a higher incidence than coronary artery bypass grafting. Risk factors independently associated with IE included male sex, age at surgery, diabetes mellitus, and peripheral vascular disease. Conclusions: CIED implantation within 30 days after cardiac surgery is associated with an increased long-term risk of IE and subsequent mortality. The type of surgery and patient comorbidities influence the risk. CLINICAL PERSPECTIVE: What is new?: In this large nationwide registry study, cardiac implantable electronic devices (CIEDs) placed within 30 days after cardiac surgery were associated with a substantial and persistent risk of infective endocarditis. The risk of infective endocarditis was influenced by the type of cardiac surgery and patient-specific factors, rather than the timing of device implantation. What are the clinical implications?: Among post–cardiac surgery patients at elevated risk for infective endocarditis (e.g., those undergoing valvular procedures) who require a CIED, selecting devices associated with lower infection risk—such as leadless pacemakers or non-transvenous ICDs—may be a preferable strategy when appropriate. The optimal timing of CIED implantation after cardiac surgery remains uncertain. When delaying implantation, the rationale should center on allowing for potential recovery of conduction abnormalities, rather than attempting to mitigate the risk of device-related infection.
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19) , e043026
Outcomes in Early Postoperative Versus Late New‐Onset Atrial Fibrillation After Coronary Artery Bypass Grafting
Background: It is unclear whether new‐onset postoperative atrial fibrillation (POAF) early after coronary artery bypass grafting (CABG) is associated with a similar risk of adverse outcomes as new‐onset atrial fibrillation occurring later after CABG. Methods: All patients treated with CABG in Sweden from 2007 to 2020 were investigated. Individual patient data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies) registry and 3 other prospective national registries were merged. The adjusted incidences of all‐cause mortality, ischemic stroke, any thromboembolism, heart failure hospitalization, and major bleeding within 12 months after debut of POAF (AF occurring before hospital discharge) or Late AF (new‐onset AF occurring between 3 months and 3 years after CABG) were compared by multivariable Poisson regression analysis, adjusted for time‐updated patient characteristics and comorbidities. Results: Out of 35 329 patients, 10 609 (30.0%) developed POAF and 628 (2.5%) developed Late AF. The crude mortality rate was lower in patients with POAF than in patients with Late AF (1.88 [95% CI, 1.63–2.17] versus 9.08 [95% CI, 6.92–11.82] per 100 patient‐years). The adjusted incidence rate ratios for all‐cause mortality (2.91 [95% CI, 2.10–3.95]); ischemic stroke (1.70 [95% CI, 1.15–2.44]); any thromboembolism (1.59 [95% CI, 1.11–2.22]), heart failure hospitalization (1.61 [95% CI, 1.19–2.12]); and major bleeding (1.73 [95% CI, 1.24–2.36]) were higher in patients with Late AF. Conclusions: POAF was associated with a markedly lower risk for morbidity and mortality than late new‐onset AF after CABG. POAF and late new‐onset AF after CABG are 2 different clinical entities of AF that may require different treatment strategies.
- 7 October 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (19) , e043026
Open AccessOutcomes in Early Postoperative Versus Late New‐Onset Atrial Fibrillation After Coronary Artery Bypass Grafting
Background: It is unclear whether new‐onset postoperative atrial fibrillation (POAF) early after coronary artery bypass grafting (CABG) is associated with a similar risk of adverse outcomes as new‐onset atrial fibrillation occurring later after CABG. Methods: All patients treated with CABG in Sweden from 2007 to 2020 were investigated. Individual patient data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies) registry and 3 other prospective national registries were merged. The adjusted incidences of all‐cause mortality, ischemic stroke, any thromboembolism, heart failure hospitalization, and major bleeding within 12 months after debut of POAF (AF occurring before hospital discharge) or Late AF (new‐onset AF occurring between 3 months and 3 years after CABG) were compared by multivariable Poisson regression analysis, adjusted for time‐updated patient characteristics and comorbidities. Results: Out of 35 329 patients, 10 609 (30.0%) developed POAF and 628 (2.5%) developed Late AF. The crude mortality rate was lower in patients with POAF than in patients with Late AF (1.88 [95% CI, 1.63–2.17] versus 9.08 [95% CI, 6.92–11.82] per 100 patient‐years). The adjusted incidence rate ratios for all‐cause mortality (2.91 [95% CI, 2.10–3.95]); ischemic stroke (1.70 [95% CI, 1.15–2.44]); any thromboembolism (1.59 [95% CI, 1.11–2.22]), heart failure hospitalization (1.61 [95% CI, 1.19–2.12]); and major bleeding (1.73 [95% CI, 1.24–2.36]) were higher in patients with Late AF. Conclusions: POAF was associated with a markedly lower risk for morbidity and mortality than late new‐onset AF after CABG. POAF and late new‐onset AF after CABG are 2 different clinical entities of AF that may require different treatment strategies.
- Open Access
- 16 May 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (32) , 3214-3223
Coronary artery bypass grafting with or without preoperative physiological stenosis assessment: a SWEDEHEART study
Background and Aims: Physiological flow assessment of coronary stenoses, such as fractional flow reserve, are routinely used to guide percutaneous coronary intervention, but it has not been equally recognized to guide coronary artery bypass grafting (CABG). Mid-term outcomes in CABG patients with and without preoperative flow assessment were compared. Methods: All patients with first-time isolated CABG in Sweden 2013-2020 were identified in the SWEDEHEART registry (n = 18 211), which also provided information on flow assessment. Data were linked with three mandatory national registries. Median follow-up was 3.6 years (range 0–7.5). Incidence of all-cause mortality, stroke, new myocardial infarction, new coronary angiography, and new revascularization was compared using adjusted Cox regression models. The proportional hazard assumption was violated for new angiography and revascularization. Hence, follow-up was divided into 0–2 and >2 years. Results: Overall, 2869 patients (15.8%) had flow assessment before surgery, increasing from 7.1% in 2013% to 21.5% in 2020. Patients with flow assessment were younger, had a lower EuroSCORE II, and received fewer distal anastomoses (3.0 ± 0.9 vs 3.2 ± 1, P < .001). There were no associations between flow assessment and mortality, post-discharge myocardial infarction, or stroke. New angiography and new revascularization were not significantly different 0–2 years, but preoperative flow assessment was associated with a higher risk for new angiography [adjusted hazard ratio (aHR) 1.32, 95% confidence interval (CI) 1.08–1.62, P = .008] and new revascularization (aHR 1.55, 95% CI 1.18–2.04, P = .002) >2 years after CABG. Conclusions: Preoperative flow assessment was not associated with improved clinical outcomes but with a higher risk for new angiography and new revascularization >2 years after CABG. The results suggest that the use of flow assessment with current cut-off levels may not be applicable in CABG, and further studies are needed.
- 16 May 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (32) , 3214-3223
Open AccessCoronary artery bypass grafting with or without preoperative physiological stenosis assessment: a SWEDEHEART study
Background and Aims: Physiological flow assessment of coronary stenoses, such as fractional flow reserve, are routinely used to guide percutaneous coronary intervention, but it has not been equally recognized to guide coronary artery bypass grafting (CABG). Mid-term outcomes in CABG patients with and without preoperative flow assessment were compared. Methods: All patients with first-time isolated CABG in Sweden 2013-2020 were identified in the SWEDEHEART registry (n = 18 211), which also provided information on flow assessment. Data were linked with three mandatory national registries. Median follow-up was 3.6 years (range 0–7.5). Incidence of all-cause mortality, stroke, new myocardial infarction, new coronary angiography, and new revascularization was compared using adjusted Cox regression models. The proportional hazard assumption was violated for new angiography and revascularization. Hence, follow-up was divided into 0–2 and >2 years. Results: Overall, 2869 patients (15.8%) had flow assessment before surgery, increasing from 7.1% in 2013% to 21.5% in 2020. Patients with flow assessment were younger, had a lower EuroSCORE II, and received fewer distal anastomoses (3.0 ± 0.9 vs 3.2 ± 1, P < .001). There were no associations between flow assessment and mortality, post-discharge myocardial infarction, or stroke. New angiography and new revascularization were not significantly different 0–2 years, but preoperative flow assessment was associated with a higher risk for new angiography [adjusted hazard ratio (aHR) 1.32, 95% confidence interval (CI) 1.08–1.62, P = .008] and new revascularization (aHR 1.55, 95% CI 1.18–2.04, P = .002) >2 years after CABG. Conclusions: Preoperative flow assessment was not associated with improved clinical outcomes but with a higher risk for new angiography and new revascularization >2 years after CABG. The results suggest that the use of flow assessment with current cut-off levels may not be applicable in CABG, and further studies are needed.
- Open Access
Pacemaker implantation after cardiac surgery: a contemporary, nationwide perspective
Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation estimates rely on non-contemporary studies. This study primarily aimed to explore the incidence and indications for PPM implantation at 30 days and 1 year after different cardiac surgical procedures in a modern cohort. Secondary outcomes were PPM incidence at 10 years and time from cardiac surgery to PPM implantation. Methods This nationwide population-based study included all patients in Sweden who from 2006 to 2020 underwent first-time coronary artery bypass grafting (CABG) and/or valvular surgery. Patients with previous PPM, previous or later implantable cardioverter-defibrillator (ICD) and those who underwent heart transplantation were excluded. Results Overall, 76 447 patients were included, out of which 8.2% (n=6271) received a PPM. The cumulative incidence of PPM implantation was 2.9%, 3.8% and 9.5% at 30 days, 1 year and 10 years following cardiac surgery, respectively. The main PPM indication was atrioventricular block. Tricuspid valve surgery exhibited the highest cumulative incidence for PPM both at 30 days (6.8%, 95% CI 4.3% to 10.0%) and 1 year (8.8%, 95% CI 6.0% to 12.0%) surpassing mitral valve surgery (30 day 5.3%, 95% CI 4.7% to 6.0%; 1 year 6.5%, 95% CI 5.8% to 7.3%), aortic valve surgery (30 day 4.8%, 95% CI 4.5% to 5.1%; 1 year 6.0%, 95% CI 5.6% to 6.3%) and CABG (30 day 0.74%, 95% CI 0.6% to 0.8%; 1 year 1.3%, 95% CI 1.2% to 1.3%). The incidence following combined operations (multiple valves and/or CABG) was 6.5% (95% CI 6.0% to 6.9%) and 8.1% (95% CI 7.7% to 8.6%) at 30 days and 1 year, respectively. Concomitant ablation surgery increased the risk even further (adjusted HR 9.2, 95% CI 7.9 to 10.6; pConclusions The need for PPM after cardiac surgery is substantial, primarily due to atrioventricular block. Tricuspid valve surgery is associated with the highest risk for PPM among isolated procedures. Combined procedures and concomitant surgical ablation further increase that risk.
Open AccessPacemaker implantation after cardiac surgery: a contemporary, nationwide perspective
Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation estimates rely on non-contemporary studies. This study primarily aimed to explore the incidence and indications for PPM implantation at 30 days and 1 year after different cardiac surgical procedures in a modern cohort. Secondary outcomes were PPM incidence at 10 years and time from cardiac surgery to PPM implantation. Methods This nationwide population-based study included all patients in Sweden who from 2006 to 2020 underwent first-time coronary artery bypass grafting (CABG) and/or valvular surgery. Patients with previous PPM, previous or later implantable cardioverter-defibrillator (ICD) and those who underwent heart transplantation were excluded. Results Overall, 76 447 patients were included, out of which 8.2% (n=6271) received a PPM. The cumulative incidence of PPM implantation was 2.9%, 3.8% and 9.5% at 30 days, 1 year and 10 years following cardiac surgery, respectively. The main PPM indication was atrioventricular block. Tricuspid valve surgery exhibited the highest cumulative incidence for PPM both at 30 days (6.8%, 95% CI 4.3% to 10.0%) and 1 year (8.8%, 95% CI 6.0% to 12.0%) surpassing mitral valve surgery (30 day 5.3%, 95% CI 4.7% to 6.0%; 1 year 6.5%, 95% CI 5.8% to 7.3%), aortic valve surgery (30 day 4.8%, 95% CI 4.5% to 5.1%; 1 year 6.0%, 95% CI 5.6% to 6.3%) and CABG (30 day 0.74%, 95% CI 0.6% to 0.8%; 1 year 1.3%, 95% CI 1.2% to 1.3%). The incidence following combined operations (multiple valves and/or CABG) was 6.5% (95% CI 6.0% to 6.9%) and 8.1% (95% CI 7.7% to 8.6%) at 30 days and 1 year, respectively. Concomitant ablation surgery increased the risk even further (adjusted HR 9.2, 95% CI 7.9 to 10.6; pConclusions The need for PPM after cardiac surgery is substantial, primarily due to atrioventricular block. Tricuspid valve surgery is associated with the highest risk for PPM among isolated procedures. Combined procedures and concomitant surgical ablation further increase that risk.
- Open Access
New-onset atrial fibrillation after coronary surgery and stroke risk: a nationwide cohort study
Background: New-onset postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) increases ischaemic stroke risk, yet factors influencing this risk remain unclear. We sought to identify factors associated with 1-year ischaemic stroke risk, compare the CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes, previous Stroke/transient ischaemic attack (TIA), Vascular disease, Age 65–74 years, Sex category) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) scores’ predictive abilities for ischaemic stroke, and assess oral anticoagulation (OAC) dispensing at discharge in patients with POAF.Methods: This nationwide cohort study used prospectively collected data from four mandatory Swedish national registries. All first-time isolated CABG patients who developed POAF during 2007–2020 were included. Multivariable logistic models were used to identify ischaemic stroke predictors and C-statistics to assess the predictive abilities of the CHA2DS2-VASc and ATRIA scores in patients without OAC. OAC dispensing patterns were described based on stroke-associated factors.Results: In total, 10 435 patients with POAF were identified. Out of those not receiving OAC (n=6903), 3.1% experienced an ischaemic stroke within 1 year. Advancing age (adjusted OR (aOR) 1.86 per 10-year increase, 95% CI 1.45 to 2.38), prior ischaemic stroke (aOR 18.56, 95% CI 10.05 to 34.28 at 60 years, aOR 5.95, 95% CI 3.78 to 9.37 at 80 years, interaction p2%/year, according to the CHA2DS2-VASc score, were not discharged on OAC.Conclusions: Prior ischaemic stroke, advancing age, history of heart failure and myocardial infarction were associated with 1-year ischaemic stroke risk in patients with POAF after CABG. CHA2DS2-VASc and ATRIA scores predicted stroke risk with similar accuracy as in non-surgical atrial fibrillation cohorts. OAC dispense at discharge does not seem to reflect individual stroke risk.
Open AccessNew-onset atrial fibrillation after coronary surgery and stroke risk: a nationwide cohort study
Background: New-onset postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) increases ischaemic stroke risk, yet factors influencing this risk remain unclear. We sought to identify factors associated with 1-year ischaemic stroke risk, compare the CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes, previous Stroke/transient ischaemic attack (TIA), Vascular disease, Age 65–74 years, Sex category) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) scores’ predictive abilities for ischaemic stroke, and assess oral anticoagulation (OAC) dispensing at discharge in patients with POAF.Methods: This nationwide cohort study used prospectively collected data from four mandatory Swedish national registries. All first-time isolated CABG patients who developed POAF during 2007–2020 were included. Multivariable logistic models were used to identify ischaemic stroke predictors and C-statistics to assess the predictive abilities of the CHA2DS2-VASc and ATRIA scores in patients without OAC. OAC dispensing patterns were described based on stroke-associated factors.Results: In total, 10 435 patients with POAF were identified. Out of those not receiving OAC (n=6903), 3.1% experienced an ischaemic stroke within 1 year. Advancing age (adjusted OR (aOR) 1.86 per 10-year increase, 95% CI 1.45 to 2.38), prior ischaemic stroke (aOR 18.56, 95% CI 10.05 to 34.28 at 60 years, aOR 5.95, 95% CI 3.78 to 9.37 at 80 years, interaction p2%/year, according to the CHA2DS2-VASc score, were not discharged on OAC.Conclusions: Prior ischaemic stroke, advancing age, history of heart failure and myocardial infarction were associated with 1-year ischaemic stroke risk in patients with POAF after CABG. CHA2DS2-VASc and ATRIA scores predicted stroke risk with similar accuracy as in non-surgical atrial fibrillation cohorts. OAC dispense at discharge does not seem to reflect individual stroke risk.
- Open Access
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (42) , 4536-4538
Benefit of early aortic valve replacement in asymptomatic severe aortic stenosis but questions remain
Andreas Martinsson, Anders Jeppsson; Invited editorial on “Outcome of aortic valve replacement versus conservative treatment in asymptomatic patients with
- 1 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (42) , 4536-4538
Open AccessBenefit of early aortic valve replacement in asymptomatic severe aortic stenosis but questions remain
Andreas Martinsson, Anders Jeppsson; Invited editorial on “Outcome of aortic valve replacement versus conservative treatment in asymptomatic patients with
- Open Access
- 6 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (21) , 1887-1889
Stable incidence and outcomes for patients with incident aortic stenosis: how can we translate excellent trial data into improved clinical outcomes in the population?
The incidence and evolution of the treatment strategies and outcomes over time. The findings indicate that the excellent trial results for aortic valve replacement in patients with aortic stenosis have not yet fully translated into a real-world setting. Created with BioRender.com
- 6 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (21) , 1887-1889
Open AccessStable incidence and outcomes for patients with incident aortic stenosis: how can we translate excellent trial data into improved clinical outcomes in the population?
The incidence and evolution of the treatment strategies and outcomes over time. The findings indicate that the excellent trial results for aortic valve replacement in patients with aortic stenosis have not yet fully translated into a real-world setting. Created with BioRender.com